Evidence map›Paper›PMID 38428413›Full record

ArticleStem cell reports2024

Activated mesenchymal stem/stromal cells promote myeloid cell differentiation via CCL2/CCR2 signaling.

Satoshi Yamazaki, Yo Mabuchi, Takaharu Kimura, Eriko Grace Suto, Daisuke Hisamatsu, Yuna Naraoka, Ayako Kondo, Yuzuki Azuma, Riko Kikuchi, Hidekazu Nishikii and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Satoshi YamazakiLaboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Yo MabuchiIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center, Fujita Health University, Tokyo 144-0041, Japan.
Takaharu KimuraLaboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Eriko Grace SutoIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Daisuke HisamatsuIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Yuna NaraokaIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Ayako KondoIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Yuzuki AzumaIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Riko KikuchiLaboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Hidekazu NishikiiLaboratory of Stem Cell Therapy, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan; Department of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
Soji MorishitaLaboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Marito ArakiLaboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Norio KomatsuLaboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Chihiro AkazawaIntractable Disease Research Center, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: c.akazawa.gt@juntendo.ac.jp.
Juntendo University · JPUniversity of Tsukuba · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid cells, which originate from hematopoietic stem/progenitor cells (HSPCs), play a crucial role in mitigating infections. This study aimed to explore the impact of mesenchymal stem/stromal cells (MSCs) on the differentiation of HSPCs and progenitors through the C-C motif chemokine CCL2/CCR2 signaling pathway. Murine MSCs, identified as PDGFRα

Indexed as

Chemokine CCL2Mesenchymal Stem CellsAnimalsCell DifferentiationHematopoietic Stem CellsHumansMiceReceptors, CCR2Signal TransductionCCL2 protein, humanCcl2 protein, mouseCcr2 protein, mouseChemokine CCL2Receptors, CCR2

Identifiers

PMID38428413
PMCPMC10937152
OpenAlexW4392302479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.